Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
Status:
Completed
Trial end date:
2020-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers
(ARB) can halt the progression to respiratory failure requiring transfer into the intensive
care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate
hypoxia due to the corona virus that causes COVID-19. Based on previous animal studies, the
researchers hypothesize that the addition of an ARB is beneficial in abating acute lung
injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.